News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,108 Results
Type
Article (13614)
Company Profile (109)
Press Release (248385)
Section
Business (87966)
Career Advice (465)
Deals (15328)
Drug Delivery (64)
Drug Development (36544)
Employer Resources (49)
FDA (6263)
Job Trends (6188)
News (150068)
Policy (14013)
Tag
Academia (435)
Alliances (23139)
Alzheimer's disease (361)
Approvals (6269)
Artificial intelligence (66)
Bankruptcy (143)
Best Places to Work (4349)
Biotechnology (44)
Breast cancer (60)
Cancer (399)
Career advice (407)
Cell therapy (56)
Clinical research (30554)
Collaboration (194)
Compensation (79)
COVID-19 (748)
C-suite (58)
Data (426)
Diabetes (59)
Diagnostics (1242)
Drug pricing (59)
Earnings (31581)
Employer resources (43)
Events (36899)
Executive appointments (217)
FDA (6487)
Funding (128)
Gene therapy (62)
GLP-1 (301)
Government (1270)
Healthcare (3531)
Infectious disease (768)
Inflammatory bowel disease (49)
Interviews (58)
IPO (5832)
Job creations (2050)
Job search strategy (373)
Layoffs (168)
Legal (3414)
Lung cancer (55)
Manufacturing (110)
Medical device (1273)
Medtech (1275)
Mergers & acquisitions (9564)
Metabolic disorders (185)
Neuroscience (471)
NextGen Class of 2024 (1580)
Non-profit (593)
Northern California (490)
Obesity (109)
Opinion (111)
Patents (63)
People (28552)
Pharmaceutical (67)
Phase I (7949)
Phase II (12925)
Phase III (11606)
Pipeline (197)
Policy (46)
Postmarket research (1400)
Preclinical (3178)
Radiopharmaceuticals (116)
Rare diseases (105)
Real estate (2629)
Regulatory (9878)
Research institute (563)
Resumes & cover letters (55)
Southern California (488)
Startups (1627)
United States (4827)
Vaccines (114)
Weight loss (81)
Date
Last 7 days (221)
Last 30 days (767)
Last 365 days (12466)
2024 (12418)
2023 (14253)
2022 (19560)
2021 (20071)
2020 (19040)
2019 (14887)
2018 (11716)
2017 (13889)
2016 (13132)
2015 (15474)
2014 (12421)
2013 (10594)
2012 (11398)
2011 (11923)
2010 (10888)
Location
Africa (312)
Arizona (43)
Asia (19870)
Australia (2565)
California (1152)
Canada (670)
China (137)
Colorado (46)
Connecticut (47)
Europe (38910)
Florida (180)
Illinois (133)
Indiana (95)
Japan (51)
Kansas (51)
Maryland (171)
Massachusetts (986)
Minnesota (64)
New Jersey (494)
New York (321)
North Carolina (293)
Northern California (490)
Pennsylvania (312)
South America (498)
Southern California (488)
Texas (159)
Virginia (45)
Washington State (78)
262,108 Results for "sparrow pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sparrow Pharmaceuticals Collaborates with the University of Oxford and the University of Sheffield on DC-MACS, a Phase 2 Clinical Study of Clofutriben
December 11, 2024
·
4 min read
BioForest
Sparrow Pharmaceuticals’ David Katz, PhD, to Receive Outstanding Innovation Award at the 2024 Annual Endocrine Society Conference
Sparrow Pharmaceuticals, announced today that it will be attending the Endocrine Society (ENDO) 2024 Annual Conference.
May 30, 2024
·
2 min read
Drug Development
Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor Clofutriben (SPI-62) for Polymyalgia Rheumatica at the European Congress of Rheumatology 2024
Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?”
June 6, 2024
·
1 min read
Drug Development
Sparrow Pharmaceuticals Presents Data from Ongoing Phase 2 Trial of Clofutriben (SPI-62) and Prednisolone as a Treatment for Polymyalgia Rheumatica at EULAR 2024
Sparrow Pharmaceuticals presented data from an ongoing Phase 2 clinical trial of HSD-1 inhibitor clofutriben and prednisolone in patients with polymyalgia rheumatica at the 2024 Annual European Alliance for Associations for Rheumatology that suggest HSD-1 inhibition can allow for effective treatment with glucocorticoid medicines with fewer side effects.
June 15, 2024
·
2 min read
Press Releases
Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing’s Syndrome
October 28, 2024
·
3 min read
Press Releases
Sparrow Pharmaceuticals to Present Two Abstracts at ACR Convergence 2024 and Expand Phase 2 Clinical Trial of Clofutriben with Prednisolone for Polymyalgia Rheumatica to Fifth Cohort
November 14, 2024
·
2 min read
Press Releases
Sparrow Pharmaceuticals Presented New Data on Clofutriben and Prednisolone for Polymyalgia Rheumatica Treatment at DGRh Kongress 2024
September 19, 2024
·
2 min read
Sparrow BioAcoustics Announces the Launch of Stethophone™ - Bringing the Future of Personalized Heart Care Closer to Home
Sparrow BioAcoustics [Sparrow], a pioneer in the field of bioacoustics technology, announces the launch of Stethophone™, a groundbreaking advancement in personalized heart health, exclusively on Valentine’s Day, February 14, 2024.
February 14, 2024
·
3 min read
Drug Development
Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion
Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study (NCT number: NCT05436639 ) of SPI-62.
October 24, 2023
·
3 min read
Drug Development
Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
Sparrow Pharmaceuticals has expanded its PROST! Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
September 12, 2023
·
3 min read
1 of 26,211
Next
